Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.64 |
| ▸ | TERT | O14746 | 2/20 | 0.61 |
| ▸ | DTYMK | P23919 | 4/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423008 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29959672 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29689844 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29716657 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL32665846 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29986652 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL14174120 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29690373 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL14184947 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29387073 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054360-A1 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-13 | — | — | WO | claimed |
| US-20250073334-A1 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-03-06 | — | — | US | claimed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117545509-A | Oral delivery of oligonucleotides | 四纬生物制药股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-12466859-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | MODEX THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250223554-A1 | METHODS AND COMPOSITIONS USING RECOMBINANT DENDRITIC CELLS FOR CANCER THERAPY | RENOVARO BIOPHARMA INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250161481-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20220152185-A1 | LAWSONIA INTRACELLULARIS COMPOSITIONS AND METHODS OF USING THE SAME | UNIVERSITY OF SASKATCHEWAN (CA) | 2022-05-19 | — | — | US | disclosed |
| US-20220125796-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127308-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-20220110951-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | ABBVIE DEUTSCHLAND (DE) | 2022-04-14 | — | — | US | disclosed |
| CN-114246953-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161481-A1 | TARGETED LNP DELIVERY | CD4, LCP2, CD2 | F2 4815/4885TERT 1407/4885DTYMK 2206/4885 |
| US-20220110951-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | BCL2, BCL2L2, BCL2L1 | F2 3220/4885TERT 4207/4885DTYMK 3038/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885DTYMK 437/4885 |
| US-20220125796-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | F2 2639/4885TERT 4507/4885DTYMK 3942/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | F2 2639/4885TERT 4507/4885DTYMK 3942/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885DTYMK 437/4885 |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | GPR68, LARP7, INCENP | F2 4859/4885TERT 186/4885DTYMK 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.